Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Head & Neck 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 40Triple Negative Breast Neoplasms 16Carcinoma, Transitional Cell 14Breast Neoplasms 14Small Cell Lung Carcinoma 12Urinary Bladder Neoplasms 11Melanoma 10Carcinoma, Hepatocellular 9Neoplasms 8Carcinoma, Renal Cell 8Uterine Cervical Neoplasms 6Neoplasm Metastasis 6Lung Neoplasms 6Colorectal Neoplasms 5Ovarian Neoplasms 4Lymphoma, Follicular 4Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Cholangiocarcinoma 3Brain Neoplasms 3Stomach Neoplasms 2Solid Tumors 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Kidney Neoplasms 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Everolimus 16Octreotide 6pembrolizumab 5lanreotide 5Sunitinib 5Magnetic Resonance Spectroscopy 5gallium Ga 68 dotatate 4cabozantinib 4Nivolumab 4Carboplatin 4telotristat ethyl 3lenvatinib 3arginyllysine 3Specimen Handling 3Etoposide 3Erlotinib Hydrochloride 3Bevacizumab 3surufatinib 2pazopanib 2pasireotide 2lutetium Lu 177 dotatate 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Sorafenib 2Phantoms, Imaging 2Paclitaxel 2Oxaliplatin 2Ipilimumab 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neuroendocrine Tumors × atezolizumab × Clear all
NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡